This truly is price gouging. Note that the pharmaceutical company in question is owned by a hedge-fund manager. Andrew Pollack reports in the NY Times: Specialists in infectious disease are protesting a gigantic overnight increase in the price of a 62-year-old drug that is the standard of care for treating a life-threatening parasitic infection. The […]
from Later On http://ift.tt/1OJaopM
via IFTTT
No comments:
Post a Comment